TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07757152: Phase I Clinical Study of ZL-65 Tablet in Healthy Adult Participants in China: Randomized, Double-blind, Placebo-controlled, Single/Multiple Oral Dose Escalation for Safety Tolerability, Pharmacokinetics, Preliminary Pha

Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 108 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07757152 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07757152 Rescue Dossier →